Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects.
The objective of this study was to compare the pharmacokinetic behavior of erythromycin in normal volunteers with that in subjects with alcoholic liver disease. Six normal volunteers received 500 mg erythromycin as an intravenous infusion or as two 250-mg enteric-coated tablets in a crossover fashion. The pharmacokinetics of erythromycin after intravenous administration was best described as a two-compartment model. The elimination half-life was 1.6 +/- 0.7 hours (mean +/- S.D.) after the intravenous dose and 2.0 +/- 0.7 hours after the oral dose. In patients with alcoholic liver disease the elimination half-life after oral administration of two 250-mg enteric-coated tablets was 3.2 +/- 0.5 hours, significantly different from that in normal subjects, probably due to impaired metabolism. The difference in half-life does not require dosage adjustment in this patient population. The systemic availability of erythromycin was 33.5 per cent (range 10.5 to 79.3 per cent).
D000284:Administration, Oral; D000328:Adult; D004917:Erythromycin / Q000378:metabolism*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008104:Liver Cirrhosis, Alcoholic / Q000378:metabolism*; D008297:Male; D013997:Time Factors
D004917:Erythromycin